Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: The ECLIPSE II study

Vascular Health and Risk Management

Volumn 9, Issue 1, 2013, Pages 563-573

  Offman, Elliot ^a   Marenco, Ted ^a   Ferber, Sandy ^b   Johnson, Judith ^c   Kling, Douglas ^c   Curcio, Danielle ^c   Davidson, Michael ^c  

^a Department of Paediatrics   (Canada)

^b Array Biostatistics LLC   (United States)

^c Omthera Pharmaceuticals Inc   (United States)

Author keywords

Docosahexaenoic acid; Eicosapentaenoic acid; Hypertriglyceridemia; Pharmacokinetics

Indexed keywords

DOCOSAHEXAENOIC ACID; EPANOVA; ICOSAPENTAENOIC ACID; OMEGA 3 ACID ETHYL ESTER; OMEGA 3 FATTY ACID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; FAT INTAKE; FATTY ACID BLOOD LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; LOW FAT DIET; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; NORMAL HUMAN; OPEN STUDY; PRESCRIPTION; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; TRIACYLGLYCEROL BLOOD LEVEL; YOUNG ADULT;

DOCOSAHEXAENOIC ACID; EICOSAPENTAENOIC ACID; HYPERTRIGLYCERIDEMIA; PHARMACOKINETICS;

ADMINISTRATION, ORAL; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CHOLESTEROL; DIET, FAT-RESTRICTED; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; ESTERS; FATTY ACIDS, NONESTERIFIED; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; LEAST-SQUARES ANALYSIS; MALE; MODELS, BIOLOGICAL; TRIGLYCERIDES;

EID: 84888288958     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S50464     Document Type: Article

References (22)

1. Christian JB, Bourgeois N, Snipes R, Lowe KA. Prevalence of severe (500 to 2, 000 mg/dL) hypertriglyceridemia in United States adults. Am J Cardiol. 2011;107:891-897.
2. Reiner Z, Catapano AL, De Backer G, et al. European Association for Cardiovascular Prevention and Rehabilitation. ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769-1818.
3. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation. 2002;106:3143-3421.
4. Davidson MH, Johnson J, Rooney MW, Kyle ML, Kling DF. A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: The ECLIPSE (Epanova compared to Lovaza in a pharmacokinetic single-dose evaluation) study. J Clin Lipidol. 2012;6:573-584.
5. Ikeda I, Sasaki E, Yasunami H, et al. Digestion and lymphatic transport of eicosapentaenoic and docosahexaenoic acids given in the form of triacylglycerol, free acid and ethyl ester in rats. Biochim Biophys Acta. 1995;1259:297-304.
6. Small DM. The effects of glyceride structure on absorption and metabolism. Annu Rev Nutr. 1991;11:413-434.
7. El Boustani S, Colette C, Monnier L, Descomps B, Crastes de Paulet A, Mendy F. Enteral absorption in man of eicosapentaenoic acid in different chemical forms. Lipids. 1987;22:711-714.
8. Hazra A, Tripathi SK, Ghosh A. Pharmacology and therapeutic potential of the n-3 polyunsaturated fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in fish oils. Indian J Pharmacol. 1999;31:247-264.
9. Lawson LD, Hughes BG. Human absorption of fish oil fatty acids as triacylglycerols, free acids, or ethyl esters. Biochem Biophys Res Commun. 1988;152:328-335.
10. Lawson LD, Hughes BG. Absorption of eicosapentaenoic acid and docosahexaenoic acid from fish oil triacylglycerols or fish oil ethyl esters co-ingested with a high-fat meal. Biochem Biophys Res Commun. 1988;156:960-963.
11. Beckermann B, Beneke M, Seitz I. Comparative bioavailability of eicosapentaenoic acid and docosahexaenoic acid from triglycerides, free fatty acids and ethyl esters in volunteers. Arzneimittelforschung. 1990;40:700-704.
12. Hansen JB, Grimsgaard S, Nilsen H, Nordøy A, Bønaa KH. Effects of highly purified eicosapentaenoic acid and docosahexaenoic acid on fatty acid absorption, incorporation into serum phospholipids and postprandial triglyceridemia. Lipids. 1998;33:131-138.
13. Gura K, Strijbosch R, Arnold S, McPherson C, Puder M. The role of an intravenous fat emulsion composed of fish oil in a parenteral nutrition-dependent patient with hypertriglyceridemia. Nutr Clin Pract. 2007;22:664-672.
14. Australian Government: Department of Health and Ageing. Therapeutic Goods Administration. Australian Public Assessment Report (AusPAR) for omega-3-acid ethyl esters 90. 2010. Available from: http://www.tga.gov.au/pdf/auspar/auspar-omacor.pdf. Accessed March 22, 2013.
15. Chan DC, Watts GF, Mori TA, Barrett PH, Redgrave TG, Beilin LJ. Randomized controlled trial of the effect of n-3 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral obesity. Am J Clin Nutr. 2003;77: 300-307.
16. Yahagi N, Shimano H, Hasty AH, et al. A crucial role of sterol regulatory element-binding protein-1 in the regulation of lipogenic gene expression by polyunsaturated fatty acids. J Biol Chem. 1999;274:35840-35844.
17. Davidson MH. Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. Am J Cardiol. 2006;98:27i-33i.
18. Steffen BT, Steffen LM, Tracy R, et al. Ethnicity, plasma phospholipid fatty acid composition and inflammatory/endothelial activation biomarkers in the Multi-Ethnic Study of Atherosclerosis (MESA). Eur J Clin Nutr. 2012;66:600-605.
19. Lemaitre RN, Tanaka T, Tang W, et al. Genetic loci associated with plasma phospholipid n-3 fatty acids: a meta-analysis of genome-wide association studies from the CHARGE Consortium. PLoS Genet. 2011;7:e1002193.
20. Kastelein JJP, Maki KC, Susekov A, et al. Dose response of a novel free-fatty acid formulation of omega-3 for the management of dyslipidemia in patients with severe hypertriglyceridemia EpanoVa fOr Lowering Very High TriglycErides (The EVOLVE Trial). Abstract APS.202.04 presented at the American Heart Association Scientific Sessions, Los Angeles, CA, November 6, 2012.
21. Maki KC, Orloff DG, Nicholls SJ, et al. A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk statin-treated patients with residual hypertriglyceridemia (the ESPRIT Trial). Clin Ther. 2013. 2013 Aug 30. pii:S0149-2918(13)00807-2. doi: 10.1016/j.clinthera.2013.07.420. [Epub ahead of print].
22. Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369:1090-1098.